SPARFLOXACIN
It is an aminofluoroquinoline and exerts its antibacterial activity via the inhibition of DNA replication of bacteria by inhibiting DNA gyrase activity. Its absorption begins soon after oral administration. The distribution of sparfloxacin in nasal mucosa and sinus mucosa is primarily high. It is metabolised by the liver to an inactive acylglucuronide conjugate. The terminal plasma elimination half-life is about 20 Hrs.Elimination of sparfloxacin is complete.Pneumonia, acute exacerbation of chronic bronchitis, lower respiratory tract infection, acute sinusitis, gonococcal and non-gonococcal urethritis in males.
Lower respiratory tract infections: 400 mg as single dose on the first day followed by 200 mg each day for 10 days. Acute bacterial sinusitis: 400 mg as a single dose on the first day followed by 200 mg each day for an average of 4 days. STD in males: Gonococcal urethritis: 200 mg as single dose on the first day followed by 100 mg/day for 4 days.
Quinolone hypersensitivity.
Pregnancy and lactation.
Cutaneous allergy and photosensitivity, digestive disorders. Rare cases of headache and sleep disorders, transient and moderate increases of transaminases, hypoglycemia
Antacids, digoxin.
